Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
41.07
+0.92 (2.29%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Spyre Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -155.2 | -208.02 | -338.79 | -83.82 | -65.8 | Upgrade
|
| Depreciation & Amortization | - | - | 0.96 | 1.96 | 2 | Upgrade
|
| Loss (Gain) From Sale of Assets | -10 | - | -15.53 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 132.77 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -8.09 | -11.4 | -2.32 | -0.33 | 0.55 | Upgrade
|
| Stock-Based Compensation | 37.61 | 44.83 | 25.68 | 7.11 | 8.04 | Upgrade
|
| Other Operating Activities | -27.64 | 21.71 | 102.53 | 0.43 | -0.34 | Upgrade
|
| Change in Accounts Receivable | - | - | 0.38 | 0.44 | -0.82 | Upgrade
|
| Change in Accounts Payable | 7.65 | -16.21 | -2.18 | -2.64 | 1.07 | Upgrade
|
| Change in Unearned Revenue | - | - | 0.58 | -0.88 | 3.58 | Upgrade
|
| Change in Other Net Operating Assets | -13.58 | 11.68 | -3.97 | -2.42 | -1.99 | Upgrade
|
| Operating Cash Flow | -169.25 | -157.41 | -99.91 | -80.14 | -53.72 | Upgrade
|
| Capital Expenditures | - | - | - | -0.04 | -0.57 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 0.48 | - | - | Upgrade
|
| Cash Acquisitions | - | - | 3.04 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | 7 | - | 15 | - | - | Upgrade
|
| Investment in Securities | -150.48 | -353.29 | -126.9 | 57.05 | -22.05 | Upgrade
|
| Investing Cash Flow | -143.48 | -353.29 | -108.39 | 57.01 | -22.62 | Upgrade
|
| Long-Term Debt Repaid | - | - | - | -0.42 | -0.51 | Upgrade
|
| Net Debt Issued (Repaid) | - | - | - | -0.42 | -0.51 | Upgrade
|
| Issuance of Common Stock | 314.44 | 243.89 | 84.96 | 43.1 | 1.9 | Upgrade
|
| Other Financing Activities | -5.41 | -1.84 | -5.8 | - | - | Upgrade
|
| Financing Cash Flow | 309.03 | 410.91 | 361.08 | 42.68 | 1.39 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | -0 | 0.03 | -0.11 | -0.02 | Upgrade
|
| Net Cash Flow | -3.7 | -99.79 | 152.8 | 19.44 | -74.96 | Upgrade
|
| Free Cash Flow | -169.25 | -157.41 | -99.91 | -80.18 | -54.29 | Upgrade
|
| Free Cash Flow Margin | - | - | -11276.52% | -3442.76% | -289.71% | Upgrade
|
| Free Cash Flow Per Share | -2.64 | -3.35 | -14.49 | -23.78 | -20.64 | Upgrade
|
| Levered Free Cash Flow | -103.85 | -66.57 | -9.61 | -50.01 | -30.62 | Upgrade
|
| Unlevered Free Cash Flow | -103.85 | -66.57 | -9.61 | -50.01 | -30.62 | Upgrade
|
| Change in Working Capital | -5.93 | -4.53 | -5.21 | -5.5 | 1.83 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.